Skip to main content
SpringerLink
Log in

Neuroendocrine Tumors Biomarkers

  • Chapter
Abdominal Neuroendocrine Tumors

Part of the book series: Updates in Surgery ((UPDATESSURG))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kanakis G, Kaltsas G (2012) Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 26:791–802

    Article  CAS  PubMed  Google Scholar 

  2. Modlin IM, Gustafsson BI, Moss SF et al (2010) Chromogranin A biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17(9):2427–2443

    Article  PubMed  Google Scholar 

  3. Taupenot L, Harper KL, O’Connor DT (2003) The chromogranin-secretogranin family. N Engl J Med 348(12): 1134–1149

    Article  CAS  PubMed  Google Scholar 

  4. Jensen RT (1999) Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin Gastrointest Dis 10(4): 156–172

    CAS  PubMed  Google Scholar 

  5. Woltering EA, Hilton RS, Zolfoghary CM et al (2006) Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin A levels and symptom frequency. Pancreas 33(3):250–254

    Article  CAS  PubMed  Google Scholar 

  6. Stridsberg M, Eriksson B, Oberg K, Janson ET (2003) A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 177(2):337–341

    Article  CAS  PubMed  Google Scholar 

  7. Lawrence B, Gustafsson BI, Kidd M et al (2011) The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1): 111–134, viii

    Article  CAS  PubMed  Google Scholar 

  8. Sciarra A, Di SF, Autran AM et al (2009) Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int 82(2): 147–151

    Article  CAS  PubMed  Google Scholar 

  9. Sobol RE, O’Connor DT, Addison J et al (1986) Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med 105(5): 698–700

    Article  CAS  PubMed  Google Scholar 

  10. Giovanella L, Marelli M, Ceriani L et al (2001) Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers 16(4):268–272

    CAS  PubMed  Google Scholar 

  11. Gulubova M, Vlaykova T (2008) Chromogranin A-, serotonin-, synaptophysin- and vascular endothelial growth factor-positive endocrine cells and the prognosis of colorectal cancer: an immunohistochemical and ultrastructural study. J Gastroenterol Hepatol 23(10): 1574–1585

    Article  PubMed  Google Scholar 

  12. Malaguarnera M, Cristaldi E, Cammalleri L et al (2009) Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch Gerontol Geriatr 48(2):213–217

    Article  CAS  PubMed  Google Scholar 

  13. Giusti M, Sidoti M, Augeri C et al (2004) Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 150(3):299–303

    Article  CAS  PubMed  Google Scholar 

  14. Grimaldi F, Fazio N, Attanasio R et al (2014) Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 37(9):875–909

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kulke MH, Shah MH, Benson AB III et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 13(1):78–108

    Article  CAS  PubMed  Google Scholar 

  16. Kunz PL, Reidy-Lagunes D, Anthony LB et al (2013) Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 42(4): 557–577

    Article  PubMed  PubMed Central  Google Scholar 

  17. Oberg K, Knigge U, Kwekkeboom D, Perren A (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii124–vii130

    Google Scholar 

  18. Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS Consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and nonfunctional pancreatic neuroendocrine tumors. Neuroendocrinology 103(2): 153–171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Niederle B, Pape UF, Costa F et al (2016) ENETS Consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 103(2): 125–138

    Article  CAS  PubMed  Google Scholar 

  20. Yang X, Yang Y, Li Z et al (2015) Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 10(4):e0124884

    Google Scholar 

  21. Bajetta E, Ferrari L, Martinetti A et al (1999) Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86(5):858–865

    Article  CAS  PubMed  Google Scholar 

  22. Panzuto F, Severi C, Cannizzaro R et al (2004) Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27(1):6–11

    Article  CAS  PubMed  Google Scholar 

  23. Cimitan M, Buonadonna A, Cannizzaro R et al (2003) Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 14(7): 1135–1141

    Article  CAS  PubMed  Google Scholar 

  24. Berna MJ, Hoffmann KM, Long SH et al (2006) Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 85(6):331–364

    CAS  Google Scholar 

  25. Massironi S, Rossi RE, Casazza G et al (2014) Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology 100(2–3): 240–249

    Article  CAS  PubMed  Google Scholar 

  26. Massironi S, Conte D, Sciola V et al (2010) Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol 105(9):2072–2078

    Article  CAS  PubMed  Google Scholar 

  27. Yu CE, Oshima J, Hisama FM, Matthews S et al (1996) A YAC, P1, and cosmid contig and 17 new polymorphic markers for the Werner syndrome region at 8p12–p21. Genomics 35(3):431–440

    Article  CAS  PubMed  Google Scholar 

  28. O’Toole D, Grossman A, Gross D et al (2009) ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 90(2): 194–202

    Article  PubMed  Google Scholar 

  29. Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26(26):4311–4318

    Article  PubMed  PubMed Central  Google Scholar 

  30. Yao JC, Pavel M, Phan AT et al (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96(12):3741–3749

    Article  CAS  PubMed  Google Scholar 

  31. Jensen EH, Kvols L, McLoughlin JM et al (2007) Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol 14(2):780–785

    Article  PubMed  Google Scholar 

  32. Rossi RE, Garcia-Hernandez J, Meyer T et al (2015) Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med 3(9): 118

    PubMed  PubMed Central  Google Scholar 

  33. Franjevic A, Pavicevic R, Bubanovic G (2012) Differences in initial NSE levels in malignant and benign diseases of the thoracic wall. Clin Lab 58(3–1):245–252

    CAS  PubMed  Google Scholar 

  34. Vinik AI, Silva MP, Woltering EA et al (2009) Biochemical testing for neuroendocrine tumors. Pancreas 38(8):876–889

    Article  PubMed  Google Scholar 

  35. Nobels FR, Kwekkeboom DJ, Coopmans W et al (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82(8): 2622–2628

    CAS  PubMed  Google Scholar 

  36. Oberg K, Krenning E, Sundin A et al (2016) A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 5(5): 174–187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Oberg K, Modlin IM, De HW et al (2015) Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol 16(9):e435–e446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Razzore P, Arnaldi G (2016) Circulating neuroendocrine tumors biomarkers. Why? When? How? Suggestions for clinical practice from guidelines and consensus. J Cancer Metastasis Treat 2:348–356

    Article  Google Scholar 

  39. Oberg K (2011) Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 18(Suppl 1):S17–S25

    Article  CAS  PubMed  Google Scholar 

  40. Shah T, Srirajaskanthan R, Bhogal M et al (2008) Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients. Br J Cancer 99(1):72–77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Khan MS, Kirkwood AA, Tsigani T et al (2016) Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin Cancer Res 22(1):79–85

    Article  CAS  PubMed  Google Scholar 

  42. Modlin IM, Drozdov I, Kidd M (2013) The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One 8(5):e63364

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Modlin IM, Drozdov I, Alaimo D et al (2014) A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer 21(4):615–628

    Article  CAS  PubMed  Google Scholar 

  44. Kema, IP, de Vries, EG, Muskiet, FA (1995) Measurement of 5-HIAA in urine. Ann Clin Biochem 32 (Pt 1): 102–104

    Article  PubMed  Google Scholar 

  45. Mashige, F, Matsushima, Y, Kanazawa, H et al (1996) Acidic catecholamine metabolites and 5-hydroxyindoleacetic acid in urine: the influence of diet. Ann Clin Biochem 33 (Pt 1):43–49

    Article  CAS  PubMed  Google Scholar 

  46. Feldman JM (1986) Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 32(5):840–844

    CAS  PubMed  Google Scholar 

  47. Kema IP, Schellings AM, Meiborg G et al (1992) Influence of a serotonin- and dopaminerich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 38(9): 1730–1736

    CAS  PubMed  Google Scholar 

  48. Meijer WG, Kema IP, Volmer M et al (2000) Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 46(10): 1588–1596

    CAS  PubMed  Google Scholar 

  49. Cleare AJ, Keating J, Ealing J, Sherwood RA (1997) A case of coeliac disease detected via raised 5-hydroxytryptamine and 5-hydroxyindoleacetic acid. Ann Clin Biochem 34 (Pt 4):440–441

    Article  PubMed  Google Scholar 

  50. Bearcroft CP, Perrett D, Farthing MJ (1998) Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 42(1):42–46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Berna MJ, Hoffmann KM, Serrano J et al (2006) Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85(6):295–330

    CAS  Google Scholar 

  52. Jensen RT, Niederle B, Mitry E et al (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84(3): 173–182

    Article  CAS  PubMed  Google Scholar 

  53. Ito T, Cadiot G, Jensen RT (2012) Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol 18(39): 5495–5503

    Article  PubMed  PubMed Central  Google Scholar 

  54. Jensen RT (1996) Gastrointestinal endocrine tumors. Gastrinoma Bailliere’s Clin Gastroenterol 10:555–766

    Article  Google Scholar 

  55. Jensen, RT, Norton, JA (2010) Endocrine tumors of the pancreas and gastrointestinal tract. In: Feldman, M, Friedman L, Brandt L (eds) Sleisenger and Fordtran’s Gastrointestinal and liver disease, 9th edn. Saunders, Philadelphia, pp. 491–522

    Chapter  Google Scholar 

  56. Frucht H, Howard JM, Slaff JI et al (1989) Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 111(9):713–722

    Article  CAS  PubMed  Google Scholar 

  57. Frucht H, Howard JM, Stark HA et al (1989) Prospective study of the standard meal provocative test in Zollinger-Ellison syndrome. Am J Med 87(5):528–536

    Article  CAS  PubMed  Google Scholar 

  58. Roy PK, Venzon DJ, Feigenbaum KM et al (2001) Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 80(3): 189–222

    CAS  Google Scholar 

  59. Metz DC (2012) Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 10(2): 126–130

    Article  PubMed  Google Scholar 

  60. Pellicano R, De Angelis C, Resegotti A, Rizzetto M (2006) Zollinger-Ellison syndrome in 2006: concepts from a clinical point of view. Panminerva Med 48(1):33–40

    CAS  PubMed  Google Scholar 

  61. Wada M, Komoto I, Doi R, Imamura M (2002) Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J Surg 26(10): 1291–1296

    Article  PubMed  Google Scholar 

  62. Shibata C, Kakyo M, Kinouchi M et al (2013) Criteria for the glucagon provocative test in the diagnosis of gastrinoma. Surg Today 43(11): 1281–1285

    Article  CAS  PubMed  Google Scholar 

  63. Service FJ (1995) Hypoglycemic disorders N Engl J Med 332(17): 1144–1152

    Google Scholar 

  64. Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19(5):783–798

    Article  CAS  PubMed  Google Scholar 

  65. Cryer PE, Axelrod L, Grossman AB et al (2009) Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94(3):709–728

    Article  CAS  PubMed  Google Scholar 

  66. Service FJ, Dale AJ, Elveback LR, Jiang NS (1976) Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 51(7):417–429

    CAS  PubMed  Google Scholar 

  67. Hirshberg B, Skarulis MC, Pucino F et al (2001) Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab 86(2):475–477

    Article  CAS  PubMed  Google Scholar 

  68. Hoff AO, Vassilopoulou-Sellin R (1998) The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 82(8): 1585–1592

    Article  CAS  PubMed  Google Scholar 

  69. Iida K, Ohara T, Hino Y et al (2010) Glucose-responsive insulinoma in a patient with postprandial hypoglycemia in the morning. Intern Med 49(19):2123–2127

    Article  PubMed  Google Scholar 

  70. Vinik AI, Strodel WE, Eckhauser FE et al (1987) Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 14(3): 263–281

    CAS  PubMed  Google Scholar 

  71. Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5): 1469–1492

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Nikou GC, Toubanakis C, Nikolaou P et al (2005) VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 52(64): 1259–1265

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Unit, Regina Elena National Cancer Institute, Rome, Italy

    Marialuisa Appetecchia

Authors
  1. Marialuisa Appetecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosa Lauretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesca Rota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimo Carlini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marialuisa Appetecchia .

Editor information

Editors and Affiliations

  1. Department of Surgery, Division of General Surgery, S. Eugenio Hospital, Rome, Italy

    Massimo Carlini

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag Italia

About this chapter

Cite this chapter

Appetecchia, M., Lauretta, R., Rota, F., Carlini, M. (2018). Neuroendocrine Tumors Biomarkers. In: Carlini, M. (eds) Abdominal Neuroendocrine Tumors. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-3955-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-3955-1_5

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-3954-4

  • Online ISBN: 978-88-470-3955-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation